A Phase 3 interventional study of romosozumab HCP administration with PFS and romosozumab self-administration with AI/Pen in Post-Menopausal Osteoporosis, sponsored by Amgen. Completed at 46 sites in 3 countries. Open to female participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-11-23.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing romosozumab in Osteoporosis, Postmenopausal — 1 open to participants now, 2 under way, none of them phase 3. romosozumab · Osteoporosis, Postmenopausal.
Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, this one is the 6th largest by enrollment, is the only one that started in 2018, is one of 6 in phase 3, and was the 8th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 12 studies testing romosozumab in Osteoporosis, Postmenopausal is open now. Recruiting first, the newest first:
Massachusetts General Hospital
Ages 45+ · Women only
romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 55 Years to 90 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2018.
This study's enrollment of 283 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 268 across the 12 interventional studies. Of the 9 that completed or were terminated, 9 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 4 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
24 studies in Osteoporosis, Postmenopausal by Amgen: none open now, none under way, none of them phase 3. Of 24 finished, 23 (96%) have results posted.
Among the 24 studies in Osteoporosis, Postmenopausal by Amgen, this one is the 14th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2018, is one of 14 in phase 3, and was the 23rd registered.
Amgen’s Osteoporosis, Postmenopausal studies by the year they started, since 2004.
1 of the studies testing romosozumab in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, from their registry updates:
Among Amgen’s 24 in Osteoporosis, Postmenopausal:
This tab as a report to print or save as PDF → With an account.
To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis either by healthcare provider (HCP) administration with prefilled syringe (PFS) or by subject self-administration with autoinjector/pen (AI/Pen)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
female (postmenopausal status is defined as no vaginal bleeding or spotting for 12 consecutive months prior to screening)
-≥ 55 to ≤ 90 years of age at the time of informed consent
Subject has history of fragility (ie, osteoporosis-related fracture) or subject meets at least 2 of the following clinical risk factors for fracture
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the open-label treatment period, participants receive 210 mg romosozumab SC QM by HCP administration with PFS.
Drug: romosozumab HCP administration with PFS
During the open-label treatment period, participants receive 210 mg romosozumab SC QM by self-administration with AI/pen.
Device: romosozumab self-administration with AI/Pen
Drug page: Romosozumab
210 mg romosozumab SC QM by HCP administration with 2 PFS
Also known as: Evenity, AMG785
210 mg romosozumab SC QM by self-administration with 2 AI/Pens
Also known as: Evenity, AMG785
Percent Change From Baseline in Lumbar Spine BMD at Month 6
Percent change from baseline in BMD at the lumbar spine as measured by dual-energy x-ray absorptiometry (DXA).
Time frame: Baseline, Month 6
Percent Change From Baseline in Total Hip BMD at Month 6
Percent change from baseline in BMD for total hip as measured by DXA.
Time frame: Baseline, Month 6
Percent Change From Baseline in Femoral Neck BMD at Month 6
Percent change from baseline in BMD at femoral neck as measured by DXA.
Time frame: Baseline, Month 6
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Device-Related AEs, Discontinuations Due to AEs, and Deaths
AE: any untoward medical occurrence irrespective of a causal relationship with the study treatment. SAE: any untoward medical occurrence that meets at least 1 of the following criteria: results in death; is immediately life-threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important serious event. Adverse device effect: any AE related to the use of a combination product or medical device. TEAEs are those AEs occurring after first dose of study drug.
Time frame: up to Month 9 (-7/+3 days)
Number of Participants Developing Anti-Romosozumab Antibodies
Participants with a negative or no result at baseline (BL) developing anti-romosozumab antibodies postbaseline, including those who were binding antibody-positive or neutralizing antibody-positive postbaseline. 'Transient' positive results are those with a negative result at the participant's last time point tested within the study period.
Time frame: up to Month 9 (-7/+3 days)
Participants were enrolled at 36 centers in Poland, United Kingdom, and United States.
| Milestone | Romosozumab 210 mg QM: PFS | Romosozumab 210 mg QM: AI/Pen |
|---|---|---|
| Started | 141 | 142 |
| Completed 6-month treatment period | 136 | 137 |
| Completed | 126 | 131 |
| Not completed | 15 | 11 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Withdrawal by subject | 14 | 9 |
Percent change from baseline in BMD at the lumbar spine as measured by dual-energy x-ray absorptiometry (DXA).
| percent change | Romosozumab 210 mg QM: PFS | Romosozumab 210 mg QM: AI/Pen |
|---|---|---|
| Percent Change From Baseline in Lumbar Spine BMD at Month 6 | 9.2 ± 0.4 | 9.0 ± 0.5 |
Percent change from baseline in BMD for total hip as measured by DXA.
| percent change | Romosozumab 210 mg QM: PFS | Romosozumab 210 mg QM: AI/Pen |
|---|---|---|
| Percent Change From Baseline in Total Hip BMD at Month 6 | 3.7 ± 0.6 | 3.6 ± 0.3 |
Percent change from baseline in BMD at femoral neck as measured by DXA.
| percent change | Romosozumab 210 mg QM: PFS | Romosozumab 210 mg QM: AI/Pen |
|---|---|---|
| Percent Change From Baseline in Femoral Neck BMD at Month 6 | 3.4 ± 0.7 | 3.6 ± 0.5 |
AE: any untoward medical occurrence irrespective of a causal relationship with the study treatment. SAE: any untoward medical occurrence that meets at least 1 of the following criteria: results in death; is immediately life-threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important serious event. Adverse device effect: any AE related to the use of a combination product or medical device. TEAEs are those AEs occurring after first dose of study drug.
| participants | Romosozumab 210 mg QM: PFS | Romosozumab 210 mg QM: AI/Pen |
|---|---|---|
| TEAEs: All | 94 | 96 |
| TEAEs: SAEs | 7 | 4 |
| TEAEs: Leading to Study Drug Discontinuation (DC) | 7 | 15 |
| TEAEs: Fatal | 0 | 0 |
| Treatment-Related (TR) TEAEs: All | 38 | 59 |
| TR TEAEs: SAEs | 0 | 0 |
| TR TEAEs: Leading to Study Drug DC | 6 | 10 |
| TR TEAEs: Fatal | 0 | 0 |
| Device-Related (DR) TEAEs: All | 18 | 30 |
| DR TEAEs: SAEs | 0 | 0 |
| DR TEAEs: Leading to Study Drug DC | 0 | 5 |
| DR TEAEs: Fatal | 0 | 0 |
Participants with a negative or no result at baseline (BL) developing anti-romosozumab antibodies postbaseline, including those who were binding antibody-positive or neutralizing antibody-positive postbaseline. 'Transient' positive results are those with a negative result at the participant's last time point tested within the study period.
| Participants | Romosozumab 210 mg QM: PFS | Romosozumab 210 mg QM: AI/Pen |
|---|---|---|
| Binding Antibody Positive Post-BL | 21 | 22 |
| Transient Binding Antibody Positive Post-BL | 6 | 3 |
| Neutralizing Antibody Positive Post-BL | 5 | 4 |
| Transient Neutralizing Antibody Positive Post-BL | 0 | 2 |
Collected over up to Month 9 (-7/+3 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Romosozumab 210 mg SC QM by PFS | 0/141 (0%) | 7/141 (5%) | 48/141 (34%) |
| Romosozumab 210 mg SC QM by AI/Pen | 0/142 (0%) | 4/142 (2.8%) | 64/142 (45.1%) |
| Event | Romosozumab 210 mg SC QM by PFS | Romosozumab 210 mg SC QM by AI/Pen |
|---|---|---|
| Colitis ischaemicGastrointestinal disorders | 1/141 | 0/142 |
| CellulitisInfections and infestations | 1/141 | 0/142 |
| Clostridium difficile infectionInfections and infestations | 1/141 | 0/142 |
| Urinary tract infectionInfections and infestations | 1/141 | 0/142 |
| Forearm fractureInjury, poisoning and procedural complications | 1/141 | 0/142 |
| Humerus fractureInjury, poisoning and procedural complications | 1/141 | 0/142 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/141 | 0/142 |
| GlioblastomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/141 | 0/142 |
| Cerebrovascular accidentNervous system disorders | 1/141 | 0/142 |
| Deep vein thrombosisVascular disorders | 1/141 | 1/142 |
| Event | Romosozumab 210 mg SC QM by PFS | Romosozumab 210 mg SC QM by AI/Pen |
|---|---|---|
| Injection site erythemaGeneral disorders | 25/141 | 35/142 |
| Injection site swellingGeneral disorders | 11/141 | 23/142 |
| Injection site painGeneral disorders | 14/141 | 21/142 |
| NasopharyngitisInfections and infestations | 15/141 | 10/142 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/141 | 9/142 |
| HeadacheNervous system disorders | 3/141 | 9/142 |
| Upper respiratory tract infectionInfections and infestations | 2/141 | 8/142 |
| Age, Continuous(years) | Romosozumab 210 mg QM: PFS | Romosozumab 210 mg QM: AI/Pen | Total |
|---|---|---|---|
| Mean | 70.3 ± 7.1 | 69.5 ± 8.4 | 69.9 ± 7.8 |
| Sex: Female, Male(Participants) | Romosozumab 210 mg QM: PFS | Romosozumab 210 mg QM: AI/Pen | Total |
|---|---|---|---|
| Female | 141 | 142 | 283 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Romosozumab 210 mg QM: PFS | Romosozumab 210 mg QM: AI/Pen | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 4 |
| Not Hispanic or Latino | 138 | 141 | 279 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Romosozumab 210 mg QM: PFS | Romosozumab 210 mg QM: AI/Pen | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 139 | 140 | 279 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Lumbar Spine Bone Mineral Density (BMD) T-Score(T-score) | Romosozumab 210 mg QM: PFS | Romosozumab 210 mg QM: AI/Pen | Total |
|---|---|---|---|
| Mean | -2.69 ± 1.03 | -2.85 ± 1.00 | -2.77 ± 1.02 |
| Total Hip BMD T-Score(T-score) | Romosozumab 210 mg QM: PFS | Romosozumab 210 mg QM: AI/Pen | Total |
|---|---|---|---|
| Mean | -2.29 ± 0.73 | -2.30 ± 0.77 | -2.29 ± 0.75 |
| Femoral Neck BMD T-Score(T-score) | Romosozumab 210 mg QM: PFS | Romosozumab 210 mg QM: AI/Pen | Total |
|---|---|---|---|
| Mean | -2.54 ± 0.63 | -2.49 ± 0.65 | -2.52 ± 0.64 |
| Participants With Pre-Existing Anti-Romosozumab Antibodies(Participants) | Romosozumab 210 mg QM: PFS | Romosozumab 210 mg QM: AI/Pen | Total |
|---|---|---|---|
| Binding Antibody Positive at or Before BL | 3 | 0 | 3 |
| Neutralizing Antibody Positive at or Before BL | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from Feb 2018 to primary completion in Apr 2019, 14 months.
Results were first posted in Apr 2020, 11 months after primary completion.
Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 14 months is below that.
Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romosozumab
Osteoporosis, Postmenopausal →